Skip to main content
Premium Trial:

Request an Annual Quote

Quark Begins Dosing Second Patient Subgroup in Phase I Study of Ocular Neuroprotection siRNA Drug

Premium

Quark Pharmaceuticals said this week that it has dosed the first patient with recent onset of non-arteritic anterior ischemic optic neuropathy in an ongoing Phase I study of QPI-1007, its synthetic siRNA drug candidate for ocular neuroprotection.

The Phase I open-label, dose-escalation study is being conducted in the US and Israel with two patient subgroups — stratum I, which includes patients with chronic nerve atrophy and began dosing in March (GSN 3/4/2010); and stratum II, which is enrolling patients with recent onset of NAION.

The company said this week that enrollment has been completed in five of the six cohorts of stratum I and that dosing at the highest planned dose level has been initiated in this patient population "with no dose-limiting toxicities observed."

Quark plans to enroll up to 30 NAION patients in stratum II. In addition to safety and pharmacokinetic assessments, the company will measure changes in visual acuity and visual field following the administration of QPI-1007.

The Phase I study is expected to enroll up to 66 patients in total who will receive a single intravitreal injection of QPI-1007 at varying doses with assessments of safety and tolerability for 12 months post-injection.

The company disclosed earlier this month in a filing with the US Securities and Exchange Commission that it expects preliminary results from the first patient subgroup to be available in the first quarter of next year and that dosing for NAION patients will be completed in the first half of 2011 (GSN 10/7/2010).

Quark said in the filing that it plans to ultimately develop QPI-1007 as a treatment for glaucoma and that it is still determining whether to launch a phase II trial in acute glaucoma patients and/or in NAION patients.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.